A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

Part of paid clinical trials in Phoenix, Arizona.

Sponsor
Incyte Corporation
Study ID
NCT07008118
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Myeloproliferative Neoplasms

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • INCA035784 — DRUG
    INCA035784 will be administered at the assigned dose in the dose escalation part and at the protocol defined dose in the dose expansion part.

Study Details

This study is being conducted to evaluate the safety and tolerability of INCA035784 in participants with myeloproliferative neoplasms.

Key Dates

Start date
Oct 1, 2025
Status verified
Apr 2026
Primary completion
Mar 14, 2028
Completion
Dec 14, 2029

Study Design

Enrollment
120 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Part 1a: Dose escalation
    INCA035784 will be administered at a protocol defined starting regimen in 28-day cycles as monotherapy to identify the maximum tolerated dose (MTD) and/or recommended dose for expansion (RDE\[s\]). Participants with myeloproliferative neoplasm (MPN) will enroll in this group.
  • Experimental: Part 1b: Dose expansion
    INCA035784 will be administered as monotherapy at the RDE(s) identified during Part 1a. Participants with myeloproliferative neoplasm (MPN) will enroll in this group.

Primary Outcome Measure

Number of participants with Dose Limiting Toxicities (DLTs) [ Time Frame: Up to 28 days ]

Central Contacts

Locations (12)

FacilityCityStateZIPSite coordinators
Mayo Clinic HospitalPhoenixArizona85054-
Stanford UniversityPalo AltoCalifornia94304-
Colorado Blood Cancer InstituteDenverColorado80218-
Mayo Clinic-FloridaJacksonvilleFlorida32224-
University of Chicago Medical CenterChicagoIllinois60637-
Johns Hopkins UniversityBaltimoreMaryland21287-
Icahn School of Medicine At Mount SinaiNew YorkNew York10029-
University of North Carolina At Chapel HillChapel HillNorth Carolina27514-
South Austin Medical CenterAustinTexas78704-
University of Texas Southwestern Medical Center Harold C Simmons Comprehensive Cancer Center BloodDallasTexas75235-
Huntsman Cancer Institute At University of UtahSalt Lake CityUtah84112-
Medical College of WisconsinMilwaukeeWisconsin53226-

Find similar trials in Phoenix, AZ

By research site
Mayo Clinic Hospital· Phoenix, AZStanford University· Palo Alto, CAColorado Blood Cancer Institute· Denver, COMayo Clinic-Florida· Jacksonville, FLUniversity of Chicago Medical Center· Chicago, ILJohns Hopkins University· Baltimore, MD

Related Studies